fda compounding semaglutide warning november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Diabetes advocacy group discourages use

The EU agency estimated that this condition may affect 1 in 10,000 people taking semaglutides for at least one year

Choose Klinic for Your Tirzepatide Treatment in Wickenburg In Wickenburg, Arizona, Klinic stands out by offering seamless insurance integration and enhanced convenience: Comprehensive Insurance Acceptance : Pre-visit insurance verification and acceptance of all major plans

Booking a retreat where the main activity is finishing a book (does anyone else fall asleep 7 pages in?!)

Most Common Side Effects: Just like other GLP-1 medications, gastrointestinal issues were the most common: Nausea (especially during dose increases) Diarrhea Vomiting Constipation Abdominal pain The frequency: Higher with 8 mg and 12 mg doses compared to lower doses

Severe, persistent upper abdominal pain, with or without vomiting, should prompt urgent medical assessment